To the Editor:

We would like to express our keen interest in the article published in a recent issue of *Critical Care* by Abe and colleagues \[[@CR1]\], who investigated the effect of misdiagnosis or unidentified site of infection at initial examination on in-hospital mortality. The authors found that misdiagnosis of the initial site of infection was associated with a \> 10% increase in in-hospital mortality among patients with infection. However, we believe that a number of factors potentially affecting the results of this study should be discussed.

Firstly, it is unclear whether the treatments for the initial diagnoses were appropriate. Although data regarding the site of infection and initial vital signs was provided, information about the duration before escalation and/or de-escalation to appropriate antibiotics according to the accurately diagnosed site of infection and pathogens was lacking. The information on appropriate fluid resuscitation and/or circulatory supports was also lacking. As delayed and inappropriate administration of antibiotics and insufficient fluid resuscitation have previously been associated with poor outcomes \[[@CR2], [@CR3]\], these factors may have affected the results of this study.

Secondly, it would be useful to have more information about the presence, if any, of antibiotic-resistant bacterial infections in this study. Infection with multidrug-resistant bacteria has been associated with poor outcomes \[[@CR4]\], and the severity of drug resistance could vary between different tertiary hospitals. Therefore, this may confound the findings of this study.

Lastly, information on mixed etiology with multiple pathogens seems lacking. The authors defined patients according to the predominant pathogens, and complicated infections were not further defined. However, patients frequently suffer from multiple pathogens in the tertiary hospitals, which has previously been associated with poor outcomes \[[@CR5]\]. Patients who were initially misdiagnosed in this study may have had a more complicated condition than the correctly diagnosed patients. Therefore, we speculate that mixed infection may be a confounding factor affecting the poor outcomes observed.

In conclusion, we believe that clarification of these issues by the authors would be helpful to better understand the effects of misdiagnosed site of infection at initial examinations on patient outcomes.

This comment refers to the article available at 10.1186/s13054-019-2475-9.
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We thank Suzuki et al. for their interest in and comments regarding our study, which is a secondary analysis of an emergency room (ER) subset of the Sepsis Prognostication in Intensive Care Unit and ER (SPICE-ER) study from 2017 to 2018 \[[@CR1]\]. As we mentioned, although the results of our study were limited, we obtained answers for some questions posed by Suzuki et al. using data from the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma (FORECAST) study conducted from 2016 to 2017 \[[@CR6]\] because the SPICE-ER study included 35 emergency departments (EDs) in 59 FORECAST institutions, which had more data compared with the SPICE-ER study on their clinical practices of interest.

In the FORECAST study, carbapenem was most commonly used after initial diagnoses (55%) followed by tazobactam/piperacillin (21%) and vancomycin (18%) \[[@CR6]\]. Most patients (84%) received broad-spectrum antibiotics within 3 h of sepsis recognition. However, we found no information on the escalation or de-escalation of antibiotics. Few studies have focused on antibiotic stewardship in patients with sepsis. In the FORECAST study, approximately 90% of patients achieved sepsis care bundle 2012 \[[@CR7]\] about supportive therapy with fluid resuscitation and vasopressors for sepsis. Our microbiologic blood culture results did not include data on antibiotic-resistant pathogens. Despite this, few patients were probably infected by antibiotic-resistant pathogens because we exclusively chose patients from EDs for the SPICE study \[[@CR1]\]. Even if antibiotic-resistant pathogens were present, the most important pathogens would have been covered by the chosen antibiotics. Complicated patients may have had multiple infection sites and mixed pathogens. However, empirical treatments consider possible entry sites, infected sites, and predominant pathogens even in the absence of confirmed infections such as primary bacteremia. Therefore, the influence of confounding factors which Suzuki et al. indicated may have been small.

Diagnosing the infection site is crucial for reasons other than ensuring the right antibiotic choice \[[@CR1], [@CR6]\], and further studies need to focus on this issue. Our results suggest that time-sensitive treatments only with broad-spectrum antibiotics may warrant reconsideration. Moreover, renewing focus on ensuring precise diagnosis for choosing more appropriate antibiotics and improving subsequent treatments including resuscitation, adjunctive therapies, and definitive therapies is essential.
